Amlator

Leaflet accompanying the packaging: patient information

Amlator, 10 mg + 5 mg, film-coated tablets

Amlator, 10 mg + 10 mg, film-coated tablets

Amlator, 20 mg + 10 mg, film-coated tablets

Atorvastatin + Amlodipine

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. This medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Amlator and what is it used for
• 2. Important information before taking Amlator
• 3. How to take Amlator
• 4. Possible side effects
• 5. How to store Amlator
• 6. Contents of the pack and other information

1. What is Amlator and what is it used for

Amlator is a combination product that contains two active substances: atorvastatin and amlodipine.
Atorvastatin belongs to a group of medicines called statins, which are lipid-regulating medicines.
Amlodipine belongs to a group of medicines called calcium antagonists, which have a vasodilating effect on blood vessels.
Amlator is indicated as a substitute for patients whose condition is adequately controlled with amlodipine and atorvastatin administered concomitantly at the same dose as in the combination product. Amlator is used to treat high blood pressure in adult patients (with chronic stable angina pectoris (or without it) and (or) Prinzmetal's angina), who have one of the following conditions:

• high cholesterol levels (primary hypercholesterolemia) or high cholesterol and triglyceride levels (combined or mixed hyperlipidemia),
• hereditary high cholesterol levels (homozygous familial hypercholesterolemia),
• prevention of cardiovascular events in adult patients at high risk of a first cardiovascular event, in addition to measures aimed at reducing other risk factors.

Amlator is not intended for initial treatment. During treatment with Amlator, the use of its individual components (medicines containing amlodipine and atorvastatin) should be discontinued.
During treatment, a standard low-cholesterol diet should be followed.
The doctor may decide to use Amlator if they find that both active substances are suitable for the patient, or if the patient has already taken medicines containing these active substances.

2. Important information before taking Amlator

When not to take Amlator

• if the patient is allergic to amlodipine, atorvastatin, or if the patient is allergic to a group of medicines called calcium channel blockers or to any other medicines similar to atorvastatin used to lower lipid levels in the blood, or to any of the other ingredients of this medicine (listed in section 6),
• if the patient has severe low blood pressure (hypotension),
• if the patient has aortic stenosis (narrowing of the aortic valve) or cardiogenic shock (a condition in which the heart does not supply enough blood to the body),
• if the patient has heart failure after a heart attack,
• if the patient has liver disease,
• if the patient has abnormal liver function test results of unknown cause,
• in women of childbearing potential who are not using effective methods of contraception,
• in pregnant or breastfeeding women,
• if the patient is taking fusidic acid orally or by injection in the last 7 days. Taking fusidic acid with Amlator may lead to serious muscle damage (rhabdomyolysis).

Warnings and precautions

Before starting treatment with Amlator, the patient should discuss it with their doctor or pharmacist

• if the patient has heart failure,
• if the patient has recently had a heart attack,
• if the patient has acute high blood pressure (hypertensive crisis),
• if the patient has had a stroke with bleeding into the brain or if the patient has small fluid-filled spaces in the brain, which are a consequence of a previous stroke,
• in case of kidney problems,
• in case of hypothyroidism,
• in case of recurring or unexplained muscle pain or muscle problems in the past or similar problems in relatives,
• if the patient has or has had myasthenia (a disease that causes general muscle weakness, including in some cases muscles involved in breathing) or ocular myasthenia (a disease that causes muscle weakness in the eyes), as statins can sometimes exacerbate the symptoms of the disease or lead to the development of myasthenia (see section 4),
• in case of muscle problems in the past when taking other lipid-lowering medicines (e.g., other statins or fibrates),
• in case of regular consumption of large amounts of alcohol,
• in case of liver disease in the past,
• in patients over 70 years of age,
• if the patient is taking or has taken fusidic acid orally or by injection in the last 7 days. Taking fusidic acid with Amlator may lead to serious muscle damage (rhabdomyolysis).

The patient should consult a doctor or pharmacist before taking Amlator

• if the patient has severe respiratory failure.

In patients who are in any of the above situations, the doctor will order a blood test before starting treatment with Amlator and probably during treatment to monitor the risk of muscle-related side effects. The risk of muscle-related side effects, such as rhabdomyolysis, increases when taking certain medicines (see section 2 "Amlator and other medicines").
The doctor or pharmacist should also be informed if muscle weakness persists. To diagnose and treat this condition, additional tests and medications may be necessary.
Patients with diabetes or those at risk of developing diabetes will be under close medical supervision while taking this medicine. Patients with high blood sugar and lipid levels, overweight, and high blood pressure may be at risk of developing diabetes.

Children and adolescents

Amlator is not recommended for children and adolescents due to a lack of data on safety and efficacy.

Amlator and other medicines

The patient should tell their doctor or pharmacist about all medicines they are taking or have recently taken, as well as any medicines they plan to take.
Some medicines may change the effect of Amlator, and Amlator may affect the effect of other medicines. Such interactions may lead to reduced efficacy of one or both medicines.
This may increase the risk of side effects, including the serious muscle disease called rhabdomyolysis, described in section 4.

• Certain antibiotics or antifungal medicines, such as erythromycin, clarithromycin, telithromycin, ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole, rifampicin.
• Other lipid-regulating medicines, such as gemfibrozil, other fibrates, colestyramine, simvastatin.
• Certain calcium channel blockers used for angina or high blood pressure, such as diltiazem; heart rhythm regulators, such as digoxin, verapamil, amiodarone.
• Immunosuppressants, such as cyclosporine.
• Letermowir, a medicine used to prevent cytomegalovirus disease,
• Medicines used to treat HIV infection, such as ritonavir, lopinavir, atazanavir, indinavir, darunavir, nelfinavir, combination therapy with tipranavir/ritonavir, etc.
• Certain medicines used to treat hepatitis C, such as telaprevir, boceprevir, and a combination product containing elbasvir and grazoprevir, ledipasvir and sofosbuvir.
• Other medicines known to interact with Amlator, including ezetimibe (which lowers cholesterol), warfarin (which reduces blood clotting), oral contraceptives, stiripentol (an antiepileptic medicine), cimetidine (used to treat heartburn and stomach ulcers), phenazon (a pain reliever), colchicine (used to treat gout), and antacids (medicines used to treat indigestion, containing aluminum or magnesium).
• Daptomycin (a medicine used to treat complicated skin and soft tissue infections and bacteremia).
• Dantrolene (an injection used to treat severe body temperature disorders).
• Tacrolimus, sirolimus, temsirolimus, and everolimus (medicines used to modify the immune system).
• Over-the-counter medicines: St. John's Wort (Hypericum perforatum) preparations.
• If the patient must take fusidic acid orally to treat bacterial infections, they should periodically stop taking Amlator. The doctor will say when it will be safe to return to taking Amlator. Taking Amlator with fusidic acid can rarely lead to muscle weakness, tenderness, or pain (rhabdomyolysis). More information on rhabdomyolysis can be found in section 4.

Amlator in combination with fusidic acid may rarely lead to muscle weakness, tenderness, or pain (rhabdomyolysis).

Amlator may increase the blood pressure-lowering effect of other antihypertensive medicines.

Amlator with food and drink and alcohol

To obtain information on taking Amlator, see section 3. The following products should be noted:
Grapefruit juice
Patients taking Amlator should not consume grapefruit juice or grapefruits, as they may increase the levels of the active substance amlodipine in the blood, which may lead to an unexpected increase in the blood pressure-lowering effect of Amlator.
Alcohol
While taking Amlator, the patient should avoid consuming excessive amounts of alcohol.
For more information, see section 2, "Warnings and precautions".

Pregnancy and breastfeeding

Amlator should not be taken if the woman is pregnant or plans to become pregnant.
It has been shown that small amounts of amlodipine pass into breast milk. Amlator should not be taken if the woman is breastfeeding.
Amlator should not be taken during breastfeeding.
The safety of Amlator in pregnancy and breastfeeding has not been established. In pregnancy, during breastfeeding, or if pregnancy is suspected, or if the patient plans to become pregnant, they should consult their doctor or pharmacist before taking this medicine.

Driving and using machines

Taking this medicine usually does not affect the ability to drive or use machines. If the tablets cause nausea, dizziness, fatigue, or headache and blurred vision, the patient should not drive or use machines in this case.

Amlator contains sodium carboxymethylcellulose

The medicine contains less than 1 mmol (23 mg) of sodium per film-coated tablet, which means that the medicine is considered "sodium-free".

3. How to take Amlator

This medicine should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
Before starting treatment, the doctor will recommend a low-cholesterol diet; this diet should be continued while taking Amlator.

Adults

The dose of Amlator is determined by the doctor. They will decide whether the patient should take 1 film-coated tablet of Amlator 10 mg + 5 mg, Amlator 10 mg + 10 mg, or Amlator 20 mg + 10 mg once a day.
The maximum daily dose is one film-coated tablet of Amlator 20 mg + 10 mg.
The tablets should be swallowed whole with water; they can be taken at any time of day, with or without food. However, the patient should try to take the tablet at the same time every day.
The patient should follow the doctor's recommendations regarding diet, especially a low-fat diet, regularly exercise, and not smoke.
The duration of treatment with Amlator is determined by the doctor.
If the patient feels that the effect of Amlator is too strong or too weak, they should consult their doctor.

Patients over 70 years of age

In patients over 70 years of age, there is no need to modify the dose.

Use in children and adolescents

Amlator is not recommended for children and adolescents.

Kidney function disorders

No dose adjustment is necessary in this group of patients.

Liver function disorders

Amlator should be used with caution in this group of patients; regular monitoring of liver function should be performed.

Overdose of Amlator

Taking too many tablets may cause a drop in blood pressure, even to a dangerously low level. Dizziness, lightheadedness, fainting, or weakness may occur. If the drop in blood pressure is severe, shock may occur. The patient's skin may be cool and moist, and they may lose consciousness. In case of an overdose of Amlator, the patient should contact the nearest hospital or doctor for advice. They should take the remaining tablets, packaging, and labels with them, so that the hospital staff knows what medicine has been taken.
Even 24-48 hours after taking the medicine, shortness of breath due to excess fluid accumulating in the lungs (pulmonary edema) may occur.

Missed dose of Amlator

In case of a missed dose of Amlator, the patient should take the next dose at the scheduled time.
A double dose should not be taken to make up for a missed dose.

Stopping treatment with Amlator

The patient should not stop taking Amlator unless the doctor decides to stop the treatment.
In case of any further doubts about taking this medicine, the patient should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Amlator can cause side effects, although not everybody gets them.

If the patient experiences any of the following serious side effects or symptoms, they should stop taking the tablets and contact their doctor or go to the nearest hospital emergency department immediately:

Uncommon(may affect up to 1 in 100 people):

• heart rhythm disorders, irregular heartbeat.

Rare(may affect up to 1 in 1,000 people):

• severe allergic reaction causing swelling of the face, tongue, and (or) throat, which can cause severe breathing difficulties.
• severe skin reactions, including severe rash, hives, redness of the skin all over the body, severe itching, blisters, peeling, and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions.
• muscle weakness, tenderness, pain, or muscle rupture, or reddish-brown urine, especially if accompanied by malaise or high fever, which may be caused by muscle breakdown. Muscle breakdown does not always resolve, even after stopping atorvastatin, and can be life-threatening and lead to kidney problems.

Very rare(may affect up to 1 in 10,000 people):

• heart attack,
• lupus-like syndrome (including rash, joint disorders, and effects on blood cells),
• if the patient experiences unexpected bleeding or bruising, it may indicate liver problems. They should contact their doctor as soon as possible.

Other possible side effects of Amlator:
Very common(may affect more than 1 in 10 people):

• edema (swelling).

Common(may affect up to 1 in 10 people):

• drowsiness, headache, dizziness (especially at the beginning of treatment), fatigue, weakness,
• vision disorders (including double vision),
• inflammation of the nasal mucosa, sore throat, nosebleeds,
• flushing,
• palpitations (awareness of heartbeat),
• shortness of breath,
• abdominal pain, nausea, constipation, bloating, indigestion, diarrhea,
• muscle pain, muscle cramps, swelling of the ankles, joint pain, and back pain, limb pain,
• allergic reactions,
• increased blood sugar levels (if the patient has diabetes, they should carefully monitor their blood sugar levels),
• increased creatine kinase levels in the blood,
• abnormal liver function test results.

Uncommon(may affect up to 1 in 100 people):

• inflammation of the nasal mucosa (cold/ sneezing),
• cough,
• loss of appetite, weight gain, weight loss, decreased blood sugar levels (if the patient has diabetes, they should continue to carefully monitor their blood sugar levels),
• mood changes, anxiety, depression, tremors,
• numbness or tingling in the fingers of the hands and feet, decreased sensation of pain or touch, changes in taste, memory loss,
• blurred vision,
• ringing in the ears and (or) head,
• chest pain,
• heart rhythm disorders, irregular heartbeat,
• fainting, low blood pressure (hypotension),
• dry mouth, vomiting, heartburn, abdominal pain in the upper and lower abdomen, pancreatitis (inflammation of the pancreas, which can cause abdominal pain),
• hepatitis,
• hair loss, red spots on the skin, skin discoloration, rash, itchy rash, hives, urticaria, increased sweating,
• neck pain, muscle fatigue,
• urination disorders, increased need to urinate at night, frequent urination,
• erectile dysfunction (impotence), gynecomastia (discomfort or enlargement of the breasts in men),
• increased body temperature, malaise, swelling, especially of the ankles (edema),
• nightmares, insomnia,
• presence of white blood cells in the urine.

Rare(may affect up to 1 in 1,000 people):

• decreased platelet count, which can cause unexpected bleeding or bruising,
• bile duct obstruction (jaundice and yellowing of the eyes),
• disorientation,
• peripheral neuropathy (a disease of the nervous system that can cause weakness, numbness, or tingling),
• tendon damage,
• angioedema,
• rash, which can occur on the skin, or ulcers in the mouth (lichenoid drug reaction),
• purpura (purple spots on the skin).

Very rare(may affect up to 1 in 10,000 people):

• decreased white blood cell count,
• stiffness or tension of the muscles, disorders involving stiffness and (or) movement problems,
• heart attack,
• gingival hyperplasia,
• allergic reactions - symptoms may include sudden wheezing and chest pain or tightness, swelling of the eyelids, face, lips, mouth, tongue, or throat, difficulty breathing, collapse,
• photosensitivity,
• hearing loss,
• abdominal distension (gastritis),
• liver failure.

Unknown(frequency cannot be estimated from the available data):

• persistent muscle weakness,
• myasthenia (a disease that causes general muscle weakness, including in some cases muscles involved in breathing),
• ocular myasthenia (a disease that causes muscle weakness in the eyes), The patient should talk to their doctor if they experience muscle weakness in their arms or legs, worsening after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or shortness of breath.
• tremors, rigidity, mask-like face, slow movements, and shuffling gait, unsteady gait.

Possible side effects reported in connection with the use of some statins (medicines of the same type):

• sexual disorders,
• depression,
• breathing problems, including persistent cough and (or) shortness of breath or fever,
• diabetes. The risk of developing diabetes is higher in people with high blood sugar and lipid levels, overweight, and high blood pressure. The doctor will monitor the patient's condition while taking this medicine.

Reporting side effects

If side effects occur, including any side effects not listed in this leaflet, the patient should tell their doctor or pharmacist, or nurse.
Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Amlator

6. Contents of the pack and other information

What Amlator contains

The active substances of Amlator are atorvastatin and amlodipine.
Amlator, 10 mg + 5 mg, film-coated tablets contain 10 mg of atorvastatin (as atorvastatin with L-lysine) and 5 mg of amlodipine (as amlodipine besylate) per film-coated tablet.
Amlator, 10 mg + 10 mg, film-coated tablets contain 10 mg of atorvastatin (as atorvastatin with L-lysine) and 10 mg of amlodipine (as amlodipine besylate) per film-coated tablet.
Amlator, 20 mg + 10 mg, film-coated tablets contain 20 mg of atorvastatin (as atorvastatin with L-lysine) and 10 mg of amlodipine (as amlodipine besylate) per film-coated tablet.

Other ingredients

Core:
calcium carbonate,
microcrystalline cellulose (type 102),
maize starch paste,
sodium carboxymethylcellulose (type A),
calcium oxide,
hydroxypropylcellulose,
Polysorbate 80,
silica, colloidal, anhydrous,
magnesium stearate.
Coating (Opadry II 85F 18422 White):
polyvinyl alcohol, partially hydrolyzed,
titanium dioxide (E171),
macrogol 4000,
talc.

What Amlator looks like and contents of the pack

Amlator, 10 mg + 5 mg, film-coated tablets are white, round, biconvex film-coated tablets, approximately 9.0 mm in diameter. One side is engraved with "CE3", and the other side is smooth.
Amlator, 10 mg + 10 mg, film-coated tablets are white, round, biconvex film-coated tablets, approximately 9.0 mm in diameter. One side is engraved with "CE5", and the other side is smooth.
Amlator, 20 mg + 10 mg, film-coated tablets are white, oval, biconvex film-coated tablets, approximately 15.5 x 8.0 mm in size. One side is engraved with "CE6", and the other side is smooth.
30 and 90 film-coated tablets are packaged in white, non-transparent blisters made of PA/Aluminum/PVC//Aluminum and in a carton.
Not all pack sizes may be marketed.

Marketing authorization holder:

Gedeon Richter Plc.
1103 Budapest
Gyömrői út 19-21
Hungary

Manufacturer:

Gedeon Richter Romania S.A.
Str. Cuza Vodă Nr. 99-105
540306 Târgu-Mureş
Romania
To obtain more detailed information about the medicine and its names in other European Economic Area member states, the patient should contact:
GEDEON RICHTER POLSKA Sp. z o.o.
ul. Ks. J. Poniatowskiego 5
05-825 Grodzisk Mazowiecki
Phone: +48 (22)755 96 48
lekalert@grodzisk.rgnet.org

Date of last revision of the leaflet: January 2025

(( marketing authorization holder's logo))